Quantitative flow ratio or angiography for the assessment of non-culprit lesions in acute coronary syndromes, a randomized trial.

IF 3.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Clinical Research in Cardiology Pub Date : 2025-06-01 Epub Date: 2024-07-09 DOI:10.1007/s00392-024-02484-5
Helen Ullrich-Daub, Maximilian Olschewski, Boris Schnorbus, Khelifa-Anis Belhadj, Till Köhler, Markus Vosseler, Thomas Münzel, Tommaso Gori
{"title":"Quantitative flow ratio or angiography for the assessment of non-culprit lesions in acute coronary syndromes, a randomized trial.","authors":"Helen Ullrich-Daub, Maximilian Olschewski, Boris Schnorbus, Khelifa-Anis Belhadj, Till Köhler, Markus Vosseler, Thomas Münzel, Tommaso Gori","doi":"10.1007/s00392-024-02484-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing percutaneous coronary intervention for acute coronary syndromes often have multivessel disease (MVD). Quantitative flow ratio (QFR) is an angiography-based technology that may help quantify the functional significance of non-culprit lesions, with the advantage that measurements are possible also once the patient is discharged from the catheterization laboratory.</p><p><strong>Aim: </strong>Our two-center, randomized superiority trial aimed to test whether QFR, as compared to angiography, modifies the rate of non-culprit lesion interventions (primary functional endpoint) and improves the outcomes of patients with acute coronary syndromes and MVD (primary clinical endpoint).</p><p><strong>Methods: </strong>In total, 202 consecutive patients (64 [56-71] years of age, 160 men) with STEMI (n = 69 (34%)), NSTEMI (n = 94 (47%)), or unstable angina (n = 39 (19%)) and MVD who had undergone successful treatment of all culprit lesions were randomized 1:1 to angiography- vs. QFR-guided delayed revascularization of 246 non-culprit stenoses (1.2/patient).</p><p><strong>Results: </strong>The proportion of patients assigned to percutaneous intervention was not different between groups (angiography group: 45 (45%) vs. QFR: 56 (55%), P = 0.125; relative risk = 0.80 (0.60-1.06)). At 12 months, a primary clinical endpoint event (composite of death, nonfatal myocardial infarction, revascularization, and significant angina) occurred in 24 patients (angiography-guided) and 23 patients (QFR-guided; P = 0.637, HR = 1.16 [0.63-2.15]). None of its components was different between groups.</p><p><strong>Discussion: </strong>QFR guidance based on analysis of images from the primary intervention was not associated with a difference in the rate of non-culprit lesion staged revascularization nor in the 12-month incidence of clinical events in patients with acute coronary syndromes and multivessel disease.</p><p><strong>Trial registration number: </strong>ClinicalTrials.gov Registry (NCT04808310).</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"729-737"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089241/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-024-02484-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients undergoing percutaneous coronary intervention for acute coronary syndromes often have multivessel disease (MVD). Quantitative flow ratio (QFR) is an angiography-based technology that may help quantify the functional significance of non-culprit lesions, with the advantage that measurements are possible also once the patient is discharged from the catheterization laboratory.

Aim: Our two-center, randomized superiority trial aimed to test whether QFR, as compared to angiography, modifies the rate of non-culprit lesion interventions (primary functional endpoint) and improves the outcomes of patients with acute coronary syndromes and MVD (primary clinical endpoint).

Methods: In total, 202 consecutive patients (64 [56-71] years of age, 160 men) with STEMI (n = 69 (34%)), NSTEMI (n = 94 (47%)), or unstable angina (n = 39 (19%)) and MVD who had undergone successful treatment of all culprit lesions were randomized 1:1 to angiography- vs. QFR-guided delayed revascularization of 246 non-culprit stenoses (1.2/patient).

Results: The proportion of patients assigned to percutaneous intervention was not different between groups (angiography group: 45 (45%) vs. QFR: 56 (55%), P = 0.125; relative risk = 0.80 (0.60-1.06)). At 12 months, a primary clinical endpoint event (composite of death, nonfatal myocardial infarction, revascularization, and significant angina) occurred in 24 patients (angiography-guided) and 23 patients (QFR-guided; P = 0.637, HR = 1.16 [0.63-2.15]). None of its components was different between groups.

Discussion: QFR guidance based on analysis of images from the primary intervention was not associated with a difference in the rate of non-culprit lesion staged revascularization nor in the 12-month incidence of clinical events in patients with acute coronary syndromes and multivessel disease.

Trial registration number: ClinicalTrials.gov Registry (NCT04808310).

Abstract Image

用于评估急性冠状动脉综合征非冠状动脉病变的定量血流比值或血管造影随机试验。
背景:因急性冠状动脉综合征接受经皮冠状动脉介入治疗的患者通常患有多血管疾病(MVD)。定量血流比(QFR)是一种基于血管造影的技术,可帮助量化非冠状动脉病变的功能意义,其优点是患者从导管室出院后也可进行测量。目的:我们的双中心随机优越性试验旨在检验 QFR 与血管造影相比,是否能改变非冠状动脉病变介入率(主要功能终点)并改善急性冠状动脉综合征和 MVD 患者的预后(主要临床终点):共有 202 名连续的 STEMI(69 人(34%))、NSTEMI(94 人(47%))或不稳定型心绞痛(39 人(19%))和 MVD 患者(64 [56-71] 岁,160 名男性)接受了成功治疗所有罪魁祸首病变后,在血管造影与 QFR 引导下对 246 个非罪魁祸首狭窄进行延迟血管再通(1.2 人/患者):结果:接受药物治疗和经皮介入治疗的患者比例在各组之间没有差异(血管造影组 45 (45%) vs. QFR 组 45 (45%) vs. QFR 组 45 (45%) ):45(45%)对 QFR:56(55%),P=0.125;相对风险=0.80(0.60-1.06))。12 个月时,24 名患者(血管造影引导)和 23 名患者(QFR 引导;P = 0.637,HR = 1.16 [0.63-2.15])发生了主要临床终点事件(死亡、非致命性心肌梗死、血管重建和明显心绞痛的复合)。讨论:讨论:基于主要干预图像分析的 QFR 引导与急性冠状动脉综合征和多血管疾病患者非病灶分期血管再通率的差异和 12 个月临床事件发生率的差异无关:试验注册号:ClinicalTrials.gov Registry (NCT04808310)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Research in Cardiology
Clinical Research in Cardiology 医学-心血管系统
CiteScore
11.40
自引率
4.00%
发文量
140
审稿时长
4-8 weeks
期刊介绍: Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信